Semaglutide vs Retatrutide
Reviewed by the BestHealingPeptides Editorial Team ·
Semaglutide is the licensed GLP-1 monoagonist that defined the modern incretin weight-loss category; retatrutide is Eli Lilly's Phase III triple GLP-1/GIP/glucagon agonist that has produced the highest weight-loss effect sizes documented for any pharmacological approach to obesity. Both target the incretin pathway but at fundamentally different scales of receptor coverage and development maturity.
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Retatrutide
An Eli Lilly Phase III development triple agonist of the GLP-1, GIP, and glucagon receptors — the next-generation extension of tirzepatide's dual-agonist mechanism with added glucagon-receptor activation for enhanced energy expenditure. Phase II results (Jastreboff et al., NEJM 2023) demonstrated 24.2% mean body weight loss over 48 weeks at the 12 mg dose, exceeding any prior published obesity pharmacotherapy. Not yet licensed in any jurisdiction; TRIUMPH Phase III programme ongoing.
| Aspect | Semaglutide | Retatrutide |
|---|---|---|
| Receptor coverage | GLP-1R monoagonist | GLP-1R + GIPR + GCGR triple-agonist |
| Development stage | Licensed (MHRA/FDA/EMA) | Phase III (TRIUMPH programme) |
| Trade names | Ozempic, Wegovy, Rybelsus | Investigational (no trade name) |
| Peak Phase II/III weight loss | ~15% body weight at 68w (STEP) | ~24% body weight at 48w (Phase II) |
| Dosing frequency | Weekly subcutaneous | Weekly subcutaneous (Phase II protocol) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| WADA status | Prohibited (S2) | Prohibited (S2) |
| Expected regulatory filing | Filed and approved (from 2017) | Expected 2026-2027 |
Mechanism
Semaglutide is a mono-agonist at the GLP-1 receptor (GLP-1R), engineered from native GLP-1 through amino-acid substitutions (Aib at position 8, Arg at position 34) and fatty-acid conjugation for albumin binding, giving a plasma half-life supporting weekly subcutaneous dosing. GLP-1R engagement drives glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and produces central-nervous-system appetite suppression through hypothalamic and brainstem GLP-1R populations. Retatrutide extends this pharmacology across three receptors — GLP-1R, GIPR (glucose-dependent insulinotropic polypeptide receptor), and glucagon receptor (GCGR) — as a single molecule with balanced tri-agonist activity. GIPR co-agonism amplifies insulinotropic effects and may attenuate GLP-1R-related nausea; glucagon-receptor agonism increases resting energy expenditure and hepatic fat mobilisation, producing weight loss through an additional pharmacological axis beyond appetite suppression alone.
Weight-loss magnitude and clinical evidence
Semaglutide's landmark STEP obesity trial programme (Wilding et al., NEJM 2021; subsequent STEP-2 through STEP-8 publications) documented mean weight loss of approximately 15% body weight at 68 weeks on 2.4 mg weekly — the largest effect size documented at trial time for any weight-loss medication and the pharmacological benchmark for the incretin class. Retatrutide's Phase II obesity trial (Jastreboff et al., NEJM 2023) documented mean weight loss of approximately 24% body weight at 48 weeks on 12 mg weekly — a substantially larger effect size than semaglutide at comparable time points and approaching the magnitude achieved by bariatric surgery. The Phase III TRIUMPH programme (TRIUMPH-1 through TRIUMPH-CVOT) is expected to produce definitive registrational data across 2026-2027.
Regulatory status and clinical availability
Semaglutide is MHRA-, FDA-, and EMA-licensed under multiple trade names — Ozempic (type-2 diabetes), Wegovy (obesity), and Rybelsus (oral tablet formulation for diabetes). NHS prescribing is possible under specific eligibility criteria; private prescription is widely available. Retatrutide is not yet licensed anywhere as of 2026 and remains investigational, with the TRIUMPH Phase III programme running toward anticipated regulatory filings in 2026-2027. Grey-market retatrutide has emerged in research-chemical channels ahead of licensing; MHRA has issued warnings against such supply. Athletes should note both compounds are on the WADA Prohibited List category S2 (Peptide Hormones).
Safety profile expectations
Semaglutide's clinical-trial and post-marketing safety profile is well-characterised: gastrointestinal adverse events (nausea, vomiting, diarrhoea) predominate, dose-titration mitigates severity, and pancreatitis and biliary disease are documented but uncommon. Retatrutide's Phase II safety data show a broadly similar profile — gastrointestinal effects lead adverse events — with the addition of glucagon-receptor-mediated modest elevations in heart rate and blood pressure at higher doses reflecting the glucagon-agonist axis. Both compounds carry considerations for hepatic disease, retinopathy, and pregnancy, and both require careful monitoring of pancreatic and biliary function. Long-term retatrutide safety awaits the Phase III programme readout.
Choosing between them (research context)
For registered clinical use as of 2026, semaglutide is the only option — retatrutide is not yet licensed. For research contexts characterising the incretin pathway, semaglutide is the pharmacologically-defined mono-agonist standard and the reference against which multi-agonists are calibrated. For research on triple-agonist pharmacology specifically, retatrutide is the current best-characterised compound. Weight-loss magnitude differences in Phase II data suggest retatrutide will occupy a distinct clinical niche once licensed — potentially preferred for the highest-BMI populations where the additional weight-loss margin is clinically meaningful. The two are not currently substitutes so much as sequential generations of incretin-pathway therapy.
Verdict
Semaglutide is the licensed GLP-1 monoagonist and the current standard-of-care incretin therapy; retatrutide is the Phase III triple GLP-1/GIP/glucagon agonist whose Phase II data suggest weight-loss magnitudes approaching bariatric-surgery outcomes. Choose semaglutide for licensed clinical use today; monitor retatrutide's Phase III readout for the likely next-generation incretin option. Grey-market retatrutide supply carries substantial regulatory and safety risk pending licensing.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.